| 颜晓勇,陈丽君,颜华水.赛胃安胶囊治疗胃溃疡效果分析[J].中国烧伤创疡杂志,2024,(6):487~491. |
| DOI： |
| 中文关键词: 胃溃疡 雷贝拉唑肠溶胶囊 赛胃安胶囊 消化道症状 胃肠激素 炎症反应 |
| 英文关键词:Gastric ulcer Rabeprazole enteric capsule Saiweian capsule Gastrointestinal symptoms Gastrointestinal hormone Inflammatory response |
| 基金项目: |
|
| 摘要点击次数: 298 |
| 全文下载次数: 725 |
| 中文摘要: |
| 【摘要】 目的 分析探讨赛胃安胶囊治疗胃溃疡的临床效果。方法 选取 2020 年 2 月至 2023 年 2 月厦门市同安区中医医院收治的 368 例胃溃疡患者作为研究对象, 根据不同治疗方法将其分为赛胃安组 (184 例) 和雷贝拉唑组 (184 例), 赛胃安组患者在常规抗幽门螺杆菌治疗基础上加用赛胃安胶囊与雷贝拉唑肠溶胶囊, 雷贝拉唑组患者在常规抗幽门螺杆菌治疗基础上加用雷贝拉唑肠溶胶囊, 对比观察两组患者消化道症状积分、溃疡面积、胃肠激素水平、炎症因子水平及临床疗效。 结果 用药 6 周后, 赛胃安组患者胃胀胃痛、反酸、纳食减少积分与总积分以及胃泌素 (GAS)、C 反应蛋白 (CRP)、高迁移率组蛋白 B1 (HMGB1)、白细胞介素 ( IL) -6、核因子-κB (NF-κB)、肿瘤坏死因子-α (TNF-α) 水平均明显低于雷贝拉唑组( t / Z = -15.476、-2.577、-8.087?-15.051、39.356、28.254、22.623、26.256、36.451、24.021, P< 0.001、P = 0.010、P< 0.001、P< 0.001、P<0.001、P<0.001、P<0.001、P<0.001、P<0.001、P<0.001), 溃疡面积明显小于雷贝拉唑组 ( t = 32.294, P<0.001), 胃动素 (MOT)、IL-2 水平均明显高于雷贝拉唑组 (t = 23.871、30.305, P 均<0.001)。用药 6 周后, 赛胃安组患者临床治愈 144 例、好转 32 例、未愈 8 例, 明显优于雷贝拉唑组患者的临床治愈 88 例、好转 52 例、未愈 44 例 (Z= -9.770, P<0.001)。结论 在常规抗幽门螺杆菌治疗基础上, 与单纯应用雷贝拉唑肠溶胶囊相比,联合应用赛胃安胶囊与雷贝拉唑肠溶胶囊治疗胃溃疡, 更能有效改善胃肠激素水平, 降低炎症反应程度, 减轻临床症状, 临床疗效更好。 |
| 英文摘要: |
| 【Abstract】 Objective To analyze the clinical efficacy of Saiweian capsule in treating gastric ulcer. Methods 368 patients with gastric ulcers admitted to Xiamen Tong’an Traditional Chinese Medicine Hospital from February 2020 to February 2023 were enrolled as study subjects and were divided into the Saiweian group (n = 184) and the rabeprazole group (n = 184) according to the different treatment methods they received. Patients in the Saiweian group were treated with Saiweian capsule and rabeprazole enteric capsule based on the conventional anti-Helicobacter pylori treatment, whereas patients in the rabeprazole group were treated with rabeprazole enteric capsule alone based on the conventional anti-Helicobacter pylori treatment. The gastrointestinal symptoms score, ulcer area, levels of gastrointestinal hormone and inflammatory factors and clinical efficacy were compared between the two groups. Results After 6 weeks of medication, the scores and total scores of stomach distension and pain, acid reflux, diet decrease, as well as the levels of gastrin (GAS), C-reactive protein (CRP),high-mobility group protein B1 (HMGB1), interleukin (IL) -6, nuclear factor-κB (NF-κB), and tumor necrosis factor-α (TNF-α) of the patients were significantly lower in the Saiweian group compared with the rabeprazole group ( t / Z =-15.476, -2.577, -8.087, -15.051, 39.356, 28.254, 22.623, 26.256, 36.451 and 24.021, P<0.001, P= 0.010,P<0.001, P<0.001, P<0.001, P<0.001, P<0.001, P<0.001, P<0.001, P<0.001), and the ulcer area was significantly smaller (t = 32.294, P< 0.001), the levels of motilin (MOT) and IL-2 were significantly higher in the Saiweian group (t = 23.871 and 30.305, both P< 0.001). After 6 weeks of medication, 144 cases were cured, 32 cases turned better, and 8 cases were not cured in the Saiweian group, which was obviously better than the rabeprazole group ( Z =-9.770, P< 0.001) -88 cases were cured, 52 cases turned better and 44 cases were not cured. Conclusion In the treatment of gastric ulcer, besides the conventional anti?Helicobacter pylori treatment, the combined application of Saiweian capsule and rabeprazole enteric capsule, compared with the simple application of rabeprazole enteric capsule, presented much better clinical efficacy given that it is more effective in improving the levels of gastrointestinal hormones, decreasing inflammatory responses and alleviating clinical symptoms of patients. |
|
|
|
|
